Clinical Trials
4 trialsNCT05286801 2026-05-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed